Evidence map›Paper›PMID 40879326›Full record

ReviewCell biology international2025

Anti-Biofouling Coatings Based on Ultra-Slippery Surfaces.

Alexander B Tesler, Wolfgang H Goldmann

Abstract readReview
In one paragraph

Review in Cell biology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexander B TeslerDepartment of Biophysics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0003-3425-7667
Wolfgang H GoldmannDepartment of Biophysics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0003-0738-2665

Funding

Financial support was given by the DFG, award number 540989797.
6 · The paper itself

Abstract

Traditional treatment of biofouling with toxic paints or antibiotics has significant limitations and challenges, including negative impacts on surrounding ecosystems and the emergence of resistant microbial strains. Antibiotics often prove ineffective in penetrating the dense and protective structure of biofilms, rendering traditional antimicrobial approaches less effective and leading to chronic infections. Toxic paints, while initially effective in reducing microbial colonization, contribute to long-term environmental contamination and harm non-target organisms. In contrast, novel technologies such as aerophilic surfaces, a special type of superhydrophobic surface, and liquid-infused slippery surfaces offer promising alternatives to conventional biofilm management technologies. While aerophilic surfaces create a physical barrier that inhibits biofilm formation by reducing the direct contact of aqueous media with solid surfaces, liquid-infused slippery surfaces enhance the anti-biofouling effect by maintaining a protective lubricating layer that prevents organisms from settling. These nontoxic technologies not only provide a more sustainable and effective means of combating biofilms but also minimize the environmental impact associated with conventional treatments. By leveraging the unique properties of advanced materials, we can increase the durability and effectiveness of surfaces, leading to improved outcomes in various fields, including medical devices and marine applications.

Indexed as

BiofilmsBiofoulingAnti-Bacterial AgentsHydrophobic and Hydrophilic InteractionsSurface PropertiesAnti-Bacterial Agentsaerophilic surfacesair plastronanti‐biofouling coatingslubricant‐infused slippery surfacesnontoxic

Identifiers

PMID40879326
PMCPMC12519937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.